These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas. Fanghanel G; Larraza O; Villalobos M; Fanghanel L; Velasco M; Velasco F Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017 [TBL] [Abstract][Full Text] [Related]
3. [The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly]. Tokuyama T; Yoshinari M; Okamura K; Ikenoue H; Sato K; Kuroda T; Fujishima M Nihon Naibunpi Gakkai Zasshi; 1991 Feb; 67(2):65-74. PubMed ID: 1674920 [TBL] [Abstract][Full Text] [Related]
4. In vitro short-term effects of SMS 201-995, bromocriptine and TRH on growth hormone cell morphology from human pituitary adenomas. García García J; Jiménez Reina L; García Luna PP; Leal Cerro A; Astorga Jiménez R; García García-Revillo J; Bernal Valls G Histol Histopathol; 1989 Apr; 4(2):223-33. PubMed ID: 2520459 [TBL] [Abstract][Full Text] [Related]
5. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021 [TBL] [Abstract][Full Text] [Related]
6. Pituitary hormone responses to hypothalamic releasing hormones in acromegaly. Cantalamessa L; Reschini E; Catania A; Giustina G Acta Endocrinol (Copenh); 1976 Dec; 83(4):673-83. PubMed ID: 826061 [TBL] [Abstract][Full Text] [Related]
7. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. Ishibashi M; Yamaji T J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273 [TBL] [Abstract][Full Text] [Related]
8. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918 [TBL] [Abstract][Full Text] [Related]
9. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. van der Lely AJ; Harris AG; Lamberts SW Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069 [TBL] [Abstract][Full Text] [Related]
10. A case of acromegaly associated with Graves' disease. A possible role of endogenous TRH and an effect of bromocriptine on GH and TSH secretion. Demura R; Demura H; Odagiri E; Shizume K Endocrinol Jpn; 1984 Dec; 31(6):801-7. PubMed ID: 6442699 [TBL] [Abstract][Full Text] [Related]
12. Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release. Hofland LJ; van Koetsveld PM; Verleun TM; Lamberts SW Clin Endocrinol (Oxf); 1989 Jun; 30(6):601-11. PubMed ID: 2512040 [TBL] [Abstract][Full Text] [Related]
13. The dynamics of growth hormone and prolactin secretion in acromegalic patients with "mixed" pituitary tumours. Lamberts SW; Klijn JG; Kwa GH; Birkenhäger JC Acta Endocrinol (Copenh); 1979 Feb; 90(2):198-210. PubMed ID: 105530 [No Abstract] [Full Text] [Related]
14. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly. Ishibashi M; Yamaji T J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426 [TBL] [Abstract][Full Text] [Related]
15. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Teramoto A; Sanno N; Tahara S; Osamura YR Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102 [TBL] [Abstract][Full Text] [Related]
16. Glycoprotein hormone alpha-subunit response to growth hormone (GH)-releasing hormone in patients with active acromegaly. Evidence for alpha-subunit and GH coexistence in the same tumoral cell. Beck-Peccoz P; Bassetti M; Spada A; Medri G; Arosio M; Giannattasio G; Faglia G J Clin Endocrinol Metab; 1985 Sep; 61(3):541-6. PubMed ID: 2410443 [TBL] [Abstract][Full Text] [Related]
17. Evidence of a circulating growth hormone stimulating factor other than growth hormone releasing hormone in a patient with pituitary tumour and acromegaly. Hulting AL; Wersäll J; Werner S Acta Endocrinol (Copenh); 1985 Jul; 109(3):289-94. PubMed ID: 3927648 [TBL] [Abstract][Full Text] [Related]
18. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months. Schwinn G; Dirks H; McIntosh C; Köbberling J Eur J Clin Invest; 1977 Apr; 7(2):101-7. PubMed ID: 404154 [TBL] [Abstract][Full Text] [Related]
19. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly. Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]